Opendata, web and dolomites

VASA SIGNED

Vaccine Against Schistosomiasis for Africa. A Phase I clinical study of the SchistoShield® anti-schistosomiasis vaccine in adults in endemic areas of sub-Saharan Africa

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 VASA project word cloud

Explore the words cloud of the VASA project. It provides you a very rough idea of what is the project "VASA" about.

constraints    species    efficacy    manufacturing    schistoshield    vaccines    efficacious    immunogenicity    anti    chemotherapy    schistosoma    downstream    transferred    infections    manufacturer    poverty    blocking    site    immune    programs    effectiveness    global    science    se    74    forms    transmission    impacting    people    regular    schistosome    model    treatment    elimination    compromised    faso    preferred    countries    consistently    protection    ranked    disease    exhibited    reinfection    adaptive    refine    antibodies    adults    schistosomiasis    haematobium    antigengla    tropical    settings    potent    burkina    burden    project    vaccine    gene    capacity    urinary    african    techniques    sm    clinical    adjuvant    innate    egg    baboon    prophylactic    hepatic    intestinal    fecundity    therapeutic    correlates    cgmp    requested    billion    mansoni    request    epidemiological    safety    prevention    healthy    gmp    diagnostic    human    resource    urgently    resolving    expression    causing    madagascar    re    candidate    signatures    lasting    reg    endemic    transfer    data    poor    p80    mass    pathology    requiring   

Project "VASA" data sheet

The following table provides information about the project.

Coordinator
THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE 

Organization address
address: TRINITY LANE THE OLD SCHOOLS
city: CAMBRIDGE
postcode: CB2 1TN
website: www.cam.ac.uk

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Total cost 0 €
 EC max contribution 6˙619˙342 € (0%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SC1-2018-Two-Stage-RTD
 Funding Scheme RIA-LS
 Starting year 2019
 Duration (year-month-day) from 2019-06-01   to  2024-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE UK (CAMBRIDGE) coordinator 1˙537˙385.00
2    INTERNATIONAL VACCINE INSTITUTE KR (Seoul) participant 1˙217˙823.00
3    UNIVERSITY OF ANTANANARIVO MG (Antananarivo) participant 864˙420.00
4    TEXAS TECH UNIVERSITY SYSTEM US (LUBBOCK) participant 704˙831.00
5    GROUPE DE RECHERCHE ACTION EN SANTE SARL BF (OUAGADOUGOU) participant 643˙812.00
6    ACADEMISCH ZIEKENHUIS LEIDEN NL (LEIDEN) participant 612˙856.00
7    PAI LIFE SCIENCES INC. US (WILMINGTON) participant 387˙290.00
8    GOETEBORGS UNIVERSITET SE (GOETEBORG) participant 350˙000.00
9    UNIVERSITE OUAGA I PROFESSEUR JOSEPH KI-ZERBO BF (OUAGADOUGOU 03) participant 259˙672.00
10    EBERHARD KARLS UNIVERSITAET TUEBINGEN DE (TUEBINGEN) participant 41˙250.00

Map

 Project objective

Schistosomiasis is a poverty-related neglected tropical disease, impacting one billion people in 74 countries. Science ranked a schistosomiasis-vaccine as one of the top-10 vaccines urgently needed. Chemotherapy is the preferred method for schistosomiasis control; but the effectiveness of mass-treatment programs is compromised by reinfection requiring regular re-treatment. An efficacious vaccine, with long-lasting protection against all schistosomiasis forms, would impact disease control. We request funding for the clinical development of our SchistoShield®-vaccine (Sm-p80 antigenGLA-SE adjuvant) in Burkina Faso and Madagascar, where Schistosoma mansoni (causing intestinal/hepatic schistosomiasis) and S. haematobium (causing urinary schistosomiasis) are endemic. In baboon studies, SchistoShield® has been effective against all major schistosome species. It is the only vaccine candidate having consistently exhibited potent prophylactic, anti-fecundity, egg-induced pathology resolving, transmission-blocking and therapeutic efficacy. The objectives are to 1) transfer vaccine manufacturing technology for cGMP production to a European manufacturer; 2) assess the safety/immunogenicity of SchistoShield® in a Phase I clinical study in healthy African adults; 3) refine a schistosomiasis human challenge model to identify correlates of protection, innate and adaptive immune signatures, gene expression and the role of antibodies in the prevention/control of Schistosoma infections; and 4) foster a global consortium to advance research on schistosomiasis vaccines and address downstream access constraints in resource-poor settings. The funding requested will allow the clinical development of SchistoShield®. GMP production will be transferred to a European partner. African site research capacity will be improved and epidemiological burden data using novel diagnostic techniques will be used to advance clinical development to Phase 2 and potential future elimination project

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "VASA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "VASA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

INADVANCE (2019)

Patient-centred pathways of early palliative care, supportive ecosystems and appraisal standard

Read More  

INTE-AFRICA (2019)

Integrating and decentralising diabetes and hypertension services in Africa

Read More  

HAP2 (2020)

Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia

Read More